445 related articles for article (PubMed ID: 18632602)
1. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Marks JL; Gong Y; Chitale D; Golas B; McLellan MD; Kasai Y; Ding L; Mardis ER; Wilson RK; Solit D; Levine R; Michel K; Thomas RK; Rusch VW; Ladanyi M; Pao W
Cancer Res; 2008 Jul; 68(14):5524-8. PubMed ID: 18632602
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
3. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
[TBL] [Abstract][Full Text] [Related]
4. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
Arcila ME; Drilon A; Sylvester BE; Lovly CM; Borsu L; Reva B; Kris MG; Solit DB; Ladanyi M
Clin Cancer Res; 2015 Apr; 21(8):1935-43. PubMed ID: 25351745
[TBL] [Abstract][Full Text] [Related]
5. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
6. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
[TBL] [Abstract][Full Text] [Related]
7. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
8. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
10. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
11. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
12. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.
Tang X; Varella-Garcia M; Xavier AC; Massarelli E; Ozburn N; Moran C; Wistuba II
Cancer Prev Res (Phila); 2008 Aug; 1(3):192-200. PubMed ID: 19138956
[TBL] [Abstract][Full Text] [Related]
16. MEK1 gene mutation in Japanese lung adenocarcinoma patients.
Sasaki H; Hikosaka Y; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Mol Med Rep; 2009; 2(2):153-5. PubMed ID: 21475805
[TBL] [Abstract][Full Text] [Related]
17. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
18. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
20. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.
Centeno I; Blay P; Santamaría I; Astudillo A; Pitiot AS; Osorio FG; González-Arriaga P; Iglesias F; Menéndez P; Tardón A; Freije JM; Balbín M
BMC Cancer; 2011 May; 11():172. PubMed ID: 21575252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
